NCI/CMS Group Will Examine Coverage For Off-Label Cancer Drug Use
This article was originally published in The Pink Sheet Daily
Executive Summary
The collaboration between the National Cancer Institute and Centers for Medicare & Medicaid Services will work to formulate a policy that may be useful for commercial health insurance coverage of drugs, an NCI rep says.
You may also be interested in...
Antimicrobial Drug Development Could Benefit From Smaller Clinical Trials, FDA Says
Studies of drugs for resistant pathogens could apply data from susceptible pathogens, CDER’s Powers tells Antimicrobial Resistance Interagency Task Force meeting. The agency plans to issue several antimicrobial-related guidances this summer.
Antimicrobial Drug Development Could Benefit From Smaller Clinical Trials, FDA Says
Studies of drugs for resistant pathogens could apply data from susceptible pathogens, CDER’s Powers tells Antimicrobial Resistance Interagency Task Force meeting. The agency plans to issue several antimicrobial-related guidances this summer.
CMS/NCI Collaboration Will Encompass Post-Approval Studies
Memorandum of understanding will create a mechanism to identify “high-priority clinical questions.” The collaboration also will examine off-label coverage of cancer drugs and reimbursement for new technologies.